
Vaxxas Expands Global IP for Exclusive Needle-Free Vaccine Manufacturing and Sales
Vaxxas, a clinical-stage biotech company, has broadened its global intellectual property portfolio to include 42 patents, reinforcing its exclusive rights to manufacture and sell its proprietary high-density microarray patch (HD-MAP) vaccination technology across the United States, Europe, Asia, and Australia.…












